Burst Expert Illustrations & Commentaries™: The Impact of Targeted IL-17 Inhibition on the Treatment for Moderate to Severe Plaque Psoriasis

Released On
December 2, 2021

Expires On
December 2, 2022

Media Type
Internet

Completion Time
45 minutes

Specialty
Dermatology

Topic(s)
Psoriasis

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

This activity is supported by an educational grant from UCB, Inc.

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)
  • Nurses — 0.75 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward dermatologists, nurse practitioners, and physician assistants involved in the care and treatment of patients with psoriasis.

Program Overview

Psoriasis is the most common immune-mediated inflammatory disease in North America and Europe, affecting approximately 8 million Americans and 125 million people worldwide. Psoriasis is a chronic, painful, disfiguring skin condition with no clearly defined cause and no cure. The critical pathogenic pathway in psoriasis is the interleukin (IL)-23/IL-17 axis. This process leads to keratinocyte hyperproliferation manifesting as characteristic scaly plaques. The implicated cytokines are also involved in the various comorbidities associated with psoriasis, including metabolic syndrome, heart disease, and psoriatic arthritis, which tend to be underrecognized. Biologic agents have been developed to target the cytokines or cytokine receptors involved to stop the inflammation associated with psoriasis. Current research is focused on the IL-17 inhibitors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the role of IL-23/IL-17 activation in the pathophysiology of psoriasis
  • Analyze the data regarding the efficacy and safety of disease-modifying therapies targeting the IL-17 pathway for the treatment of psoriasis
  • Integrate IL-17 inhibitors into personalized treatment strategies for patients with psoriasis

Faculty

FACULTY_NAME

Vivian Laquer, MD, FAAD

Director of Clinical Research,
First OC Dermatology
Fountain Valley, CA
Assistant Clinical Professor,
University of California, Irvine
Irvine, CA


Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.75 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Vivian Laquer, MD, FAAD

  • Grant/Research Support: Takeda, CSL Behring; Consulting: Grifols, Takeda, CSL Behring
  • Speakers’ Bureau: Grifols, Takeda, CSL Behring.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.